Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada

References

• Langley JM, Wang EE, Law BJ, et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J Pediatr 1997;131(1 Pt 1):113-17
   PubMed Web of Science ®Google Scholar
• Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003;143(5 Suppl):S150-6
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immunoglobulin intravenous for the prevention of respiratory syncytial virus infections. Pediatr 2003;112:1442-6
   PubMed Web of Science ®Google Scholar
• Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23:806-14
   PubMed Web of Science ®Google Scholar
• Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008;28:471-80
   PubMed Web of Science ®Google Scholar
• Lanctôt KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32--35 weeks: a Canadian-based analysis. Curr Med Res Opin 2008;24:3223-37
   PubMed Web of Science ®Google Scholar
• Simoes EAF, Carbonell-Estrany X, Fullarton JR, et al. and European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP study. Resp Res 2008;9:78
   PubMed Web of Science ®Google Scholar
• Prais D, Danino D, Schonfeld T, et al. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey. Chest 2005;128:2765-71
   PubMed Web of Science ®Google Scholar
• Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003;143:S133-41
   PubMed Web of Science ®Google Scholar
• Willson DF, Landrigan CP, Horn SD, et al. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr 2003;143:S142-9
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization (NACI). Statement on the recommended use of monoclonal anti-RSV antibody (Palivizumab). Canada Communicable Diseases Report 2003;29:ACS-7,8
   Google Scholar
• Canadian Pediatric Society. Infectious Diseases and Immunization Committee. Palivizumab and respiratory syncytial virus immunoglobulin intravenous for the prophylaxis of respiratory syncytial virus infections in high-risk infants. Paediatr Child Health 1999;4:474-80
   PubMedGoogle Scholar
• Holman RC, Shay DK, Curns AT, et al. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J 2003;22:483-9
   PubMed Web of Science ®Google Scholar
• Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus (RSV) infection. Arch Dis Child 2008;94:99-103
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Births 2006. Livebirths, by birth weight and geography-both sexes. Available at: www.statcan.gc.ca
   Google Scholar
• Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360:588-98
   PubMed Web of Science ®Google Scholar
• Paes B, Steele S, Janes M, et al. Risk-scoring tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks’ gestational age in Canada. Curr Med Res Opin 2009;25:1585-91
   PubMed Web of Science ®Google Scholar
• Simoes EAF. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003;143:S118-26
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004;23:815-20
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero-Jimenez J, et al.; IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27:788-93
   PubMed Web of Science ®Google Scholar
• Bulkow LR, Singleton RJ, Karron RA, et al.; the Alaska RSV Study Group. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics 2002;109:210-16
   PubMed Web of Science ®Google Scholar
• Downham MA, Scott R, Sims DG, et al. Breast feeding protects against respiratory syncytial virus infections. Br Med J.1976;2:274-6
   PubMed Web of Science ®Google Scholar
• McConnochie KM, Roghmann KJ. Parental smoking, presence of older siblings, and family history of asthma increase risk of bronchiolitis. Am J Dis Child 1986;140:806-12
   PubMedGoogle Scholar
• Anderson LJ, Parker RA, Strikas RA, et al. Day-care attendance and hospitalization for lower respiratory tract illness. Pediatrics 1988;82:300-08
   PubMed Web of Science ®Google Scholar